Top-News
Neuester, zuletzt geles. Beitrag
Antworten | Hot-Stocks-Forum

Gibt's Meinungen zu Cambridge Antibody ?

Beiträge: 11
Zugriffe: 2.315 / Heute: 1
CAMBRIDGE AN. kein aktueller Kurs verfügbar
 
first-henri:

Gibt's Meinungen zu Cambridge Antibody ?

 
27.03.03 01:14
Wurde ja mal spekuliert, daß CAT G unsere geliebte MorphoSys übernehmen will. Könnte ein Top-Rebounder werden, ohne news heute stark unter Druck gekommen, über 18 % im Minus geschlossen, sollten sichere 10 % locker drin sein, morgen, meine Meinung.
Und sichere %e nehme ich gerne mit ;-))

Gibt's Meinungen zu Cambridge Antibody ? 985858

Gibt's Meinungen zu Cambridge Antibody ? 985858

Greetz f-h

Werbung

Entdecke die beliebtesten ETFs von Amundi

Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi ETF Leveraged MSCI USA Daily UCITS ETF - EUR (C/D)
Perf. 12M: +71,48%
Amundi Nasdaq-100 Daily (2x) Leveraged UCITS ETF - Acc
Perf. 12M: +59,56%
Amundi Russell 1000 Growth UCITS ETF - Acc
Perf. 12M: +38,69%
Amundi MSCI Wld Clim. Paris Align. PAB Umw. UCITS ETF DR C/D
Perf. 12M: +36,88%

first-henri:

Vielleicht 'ne Meinung von

 
27.03.03 01:19
Eskimato, Grueni, Kicky, Doc, Pavian oder 'nem Bio Spezi ?

Greetz f-h
first-henri:

latest news

 
27.03.03 01:48
Cambridge Antibody Technology - Humira(TM) Royalties  
        WEDNESDAY, MARCH 26, 2003 2:00 AM
- PR Newswire

CAMBRIDGE, England, Mar 26, 2003 /PRNewswire-FirstCall via COMTEX/ -- As announced earlier this year, Abbott Laboratories received FDA approval to market Humira(TM) earlier than expected on December 31, 2002. Humira was isolated and optimized by Cambridge Antibody Technology (Nasdaq: CATG; LSE: CAT) in collaboration with Abbott, and CAT will receive a royalty fee based on Humira sales. CAT's entitlement to royalties in relation to sales of Humira is governed by an agreement dated April 1, 1995 between Cambridge Antibody Technology Limited and Knoll Aktiengesellschaft (now a subsidiary of Abbott Laboratories).

The agreement allows for offset, in certain circumstances, of royalties due to third parties against royalties due to CAT, subject to a minimum royalty level. Abbott has indicated to CAT that it wishes to initiate discussions regarding the applicability of these royalty offset provisions for Humira. CAT's view is that these offset provisions do not apply; however this view has not been confirmed by Abbott. The proposed discussions with Abbott could lead to a range of possible outcomes. However if the royalty offset provisions were to apply this could result in a reduction in net royalties from Humira receivable by CAT compared with market expectations.

     The first royalties are due from Abbott in October 2003.

     Notes to Editors

     Cambridge Antibody Technology (CAT):

     *      CAT is a UK-based biotechnology company using its proprietary
           technologies and capabilities in human monoclonal antibodies for
           drug discovery and drug development.   Based near Cambridge, England,
           CAT currently employs around 290 people.
     *      CAT is a leader in the discovery and development of human
           therapeutic antibodies and has an advanced proprietary platform
           technology for rapidly isolating human monoclonal antibodies using
           phage display systems.   CAT has extensive phage antibody libraries,
           currently incorporating more than 100 billion distinct antibodies.
           These libraries form the basis for the Company's strategy to develop
           a portfolio of antibody-based drugs.
     *      Humira(TM) is the leading CAT-derived antibody.   Six other
           CAT-derived human therapeutic antibodies are at various stages of
           clinical trials.
     *      CAT has alliances with a large number of pharmaceutical and
           biotechnology companies to discover, develop and commercialize human
           monoclonal antibody-based products.   CAT has also licensed its
           proprietary human phage antibody libraries to several companies for
           target validation and drug discovery.   CAT's collaborators include:
           Abbott, Amgen, Amrad, Chugai, Elan, Genzyme, Human Genome Sciences,
           Merck & Co, Pharmacia and Wyeth Research.
     *      CAT is listed on the London Stock Exchange and on NASDAQ since June
           2001.   CAT raised 41m pounds in its IPO in March 1997 and 93m pounds
           in a secondary offering in March 2000.


Application of the Safe Harbor of the Private Securities Litigation Reform

Act of 1995:

This press release contains statements about Cambridge Antibody Technology Group plc ("CAT") that are forward-looking statements. All statements other than statements of historical facts included in this press release may be forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on numerous assumptions regarding CAT's present and future business strategies and the environment in which CAT will operate in the future. Certain factors that could cause CAT's actual results, performance or achievements to differ materially from those in the forward-looking statements include: market conditions, CAT's ability to enter into and maintain collaborative arrangements, success of product candidates in clinical trials, regulatory developments and competition.

SOURCE Cambridge Antibody Technology

CAT's Offer for OGS Gibt's Meinungen zu Cambridge Antibody ? 985860
       MONDAY, MARCH 24, 2003 4:36 AM
 - PR Newswire

CAMBRIDGE, England, Mar 24, 2003 /PRNewswire-FirstCall via COMTEX/ -- Cambridge Antibody Technology (LSE: CAT; Nasdaq: CATG) notes the recent press reports that Celltech (LSE: CCH; NYSE: CLL) has acquired approximately 10 per cent. of the outstanding share capital of Oxford GlycoSciences (LSE: OGS; Nasdaq: OGSI).

CAT reminds OGS shareholders that the proposed merger of CAT and OGS would be effected by way of a scheme of arrangement that would require approval by a majority in number of the shareholders who vote at the court convened meeting representing 75 per cent of the shares voted at that meeting. As a result, the proposed merger of CAT and OGS can be achieved notwithstanding Celltech's recent acquisition of OGS shares.

     Notes     Cambridge Antibody Technology (CAT):     -- CAT is a UK-based biotechnology company using its proprietary        technologies and capabilities in human monoclonal antibodies for drug        discovery and drug development. Based near Cambridge, England, CAT        currently employs around 290 people.     -- CAT is a leader in the discovery and development of human therapeutic        antibodies and has an advanced proprietary platform technology for        rapidly isolating human monoclonal antibodies using phage display        systems. CAT has extensive phage antibody libraries, currently        incorporating more than 100 billion distinct antibodies. These        libraries form the basis for the Company's strategy to develop a        portfolio of antibody-based drugs.     -- Humira(TM) is the leading CAT-derived antibody. Six other CAT-derived        human therapeutic antibodies are at various stages of clinical trials.     -- CAT has alliances with a large number of pharmaceutical and        biotechnology companies to discover, develop and commercialise human        monoclonal antibody-based products. CAT has also licensed its        proprietary human phage antibody libraries to several companies for        target validation and drug discovery. CAT's collaborators include:        Abbott, Amgen, Amrad, Chugai, Elan, Genzyme, Human Genome Sciences,        Merck & Co, Pharmacia and Wyeth Research.     -- CAT is listed on the London Stock Exchange and on NASDAQ since June        2001. CAT raised 41m pounds sterling in its IPO in March 1997 and        93m pounds in a secondary offering in March 2000.

Application of the Safe Harbor of the Private Securities Litigation Reform Act of 1995:

This press release contains statements about Cambridge Antibody Technology Group plc ("CAT") that are forward looking statements. All statements other than statements of historical facts included in this press release may be forward looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These forward looking statements are based on numerous assumptions regarding CAT's present and future business strategies and the environment in which CAT will operate in the future. Certain factors that could cause CAT's actual results, performance or achievements to differ materially from those in the forward looking statements include: market conditions, CAT's ability to enter into and maintain collaborative arrangements, success of product candidates in clinical trials, regulatory developments and competition.

SOURCE Cambridge Antibody Technology

 

Oxford GlycoSciences Plc ('OGS') Update on Merger Discussions Gibt's Meinungen zu Cambridge Antibody ? 985860
       SUNDAY, MARCH 23, 2003 2:11 PM
 - PR Newswire

OXFORD, England, Mar 23, 2003 /PRNewswire-FirstCall via COMTEX/ -- Further to the announcement by the OGS (Nasdaq: OGSI; LSE: OGS) Board on 14 March 2003 and recent press coverage regarding the Celltech offer to OGS shareholders, the OGS Board* is releasing this statement to clarify the current position regarding further discussions with Cambridge Antibody Technology Group plc ("CAT") and other potentially interested third parties.

      * OGS is continuing discussions with CAT with regard to a potential        revised proposal.      * In addition, OGS is continuing discussions with other potentially        interested third parties.

The OGS Board is committed to maximising value for OGS shareholders and continues to advise OGS shareholders to take no action in relation to the Celltech offer.

Commenting, David Ebsworth PhD, CEO of OGS, said, "There is still all to play for. We remain in active discussions with CAT with a view to obtaining a material improvement in the value of their offer. In addition, we continue to seek further offers from other potentially interested parties. With respect to recent press coverage, the proposed scheme of arrangement with CAT would not be prevented by a possible 10% holding by any party provided 75% of votes cast are in favour of the scheme. The OGS Board is fully focussed on maximising the value for our shareholders and therefore, we strongly advise shareholders to take no action at this time."

 

Cambridge Antibody Technology Reports the Development of ABthrax(TM) By Human Genome Sciences, Inc. Gibt's Meinungen zu Cambridge Antibody ? 985860
       WEDNESDAY, MARCH 19, 2003 10:35 AM
 - PR Newswire

CAMBRIDGE, England, Mar 19, 2003 /PRNewswire-FirstCall via COMTEX/ -- Cambridge Antibody Technology (LSE: CAT; Nasdaq: CATG) today acknowledges the announcement by Human Genome Sciences, Inc. (HGSI) that it has discovered and developed a human monoclonal antibody drug, ABthrax(TM), that is effective in protecting against anthrax in multiple experimental models. HGSI plans to file an Investigational New Drug application in the near future, seeking clearance from the Food and Drug Administration (FDA) to begin clinical trials in the US to evaluate the safety, tolerability and pharmacology of ABthrax in healthy adults.

CAT confirms that the ABthrax antibody was isolated and developed by HGSI from libraries it has licensed to HGSI.

Peter Chambre, CAT's Chief Executive Officer, comments "We are delighted with the success that HGSI is having in working with the libraries we licensed to them. ABthrax is the fourth human monoclonal antibody to come from CAT's collaboration with HGSI and we continue to be pleased with the productivity of this relationship."

CAT has already received a licence fee for the antibody and is entitled to receive clinical development milestones and royalties on product sales from HGSI.

The full text of the HGSI announcement is available on the HGSI website, www.hgsi.com .

Oxford GlycoSciences plc ('OGS' or the 'Company') Advice to Shareholders Gibt's Meinungen zu Cambridge Antibody ? 985860
       FRIDAY, MARCH 14, 2003 2:42 AM
 - PR Newswire

OXFORD, England, Mar 14, 2003 /PRNewswire-FirstCall via COMTEX/ -- The OGS Board* is today posting a circular to OGS Shareholders setting out its advice in relation to the offers from Cambridge Antibody Technology Group plc ("CAT") and Celltech Group plc ("Celltech").

The OGS Board continues to believe that a merger with CAT represents the best alternative for OGS Shareholders, enabling them to benefit from continued participation in the future of the combined businesses. However, given the current difference in value of the CAT Merger relative to the Celltech Offer, the OGS Board, which has been so advised by Goldman Sachs, has withdrawn its recommendation of the CAT Merger. The OGS Board intends to pursue further discussions with CAT regarding a potential revised proposal and also to seek or consider offers from other potentially interested parties.

The OGS Board, which has been so advised by Goldman Sachs, does not recommend the Celltech Offer, as it believes, as a cash offer, it does not reflect fully the value of the business and cash of OGS.

The OGS Board is advising OGS Shareholders to take no action in respect of the Celltech Offer

Eskimato:

Ach Käse.

 
27.03.03 07:04
Wenn Bio, dann derzeit nur LGND, ENDP, IVX, MLNM, SCLN, ABRX, ONXX, XOMA, NVGN, etc.

Tut mir leid, ich hab Cambridge gar nicht mehr in der WL und will mich nicht mehr derzeit damit beschäftigen. Ab einem bestimmten Zeitpunkt hab ich die Schnauze voll und schmeisse Shares in den Papierkorb.

Na ja, die Meldung könnt was sein, schreib mal wenn se drehen.

Gruss E.
Eskimato:

Equal Weight.

 
27.03.03 15:37
Hab ich eben gesehen, Gruss E.

Cambridge Antibody Technology: Equal Weight
Die Analysten des Investmenthauses Lehman Brothers stufen die Aktie des britischen Biotech-Unternehmens Cambridge Antibody Technology (CAT) von 'Overweight' auf nun 'Equal Weight' herab.

So reduziere eine Senkung der Lizenzgebühren für Humira den potentiellen Kapitalwert (NPV) von CAT. Aufgrund der Berichte von Abbott würden die Lizenzerwartungen von 5 auf 3,35 Prozent gesenkt. Dies wirke sich beim NPV je Aktie mit einem Rückgang von 265 Pence auf nun 115 Pence aus. Die Analysten sind der Ansicht, dass Abbott nach der Lizenzvereinbarung für die Cabilly-Patente mit Genentech über 3 bis 3,5 Prozent zu diesem Wert bei CAT komme. Insgesamt erwarten die Analysten keine schnelle Lösung und sehen daher Abwärtspotential.

Das Ergebnis je Aktie werde für 2002 bei -78,73 Pence und 2003 bei -84,32 Pence gesehen. Auf dem aktuellen Kursniveau von 429 Pence ergebe sich daraus ein 2003er KGV von -5,1. Das Kursziel senken die Analysten von 760 Pence auf nun 400 Pence.


first-henri:

Haben sich doch gar nicht soooo schlecht

 
17.05.03 00:52
entwickelt.
Kicky:

konnten auch Oxford Glycosciences nicht übernehmen

 
17.05.03 08:37
weil Lizenzgewinne von Humira offensichtlich zu gering waren,celltech hat übernommen
ecki:

Infos zu CAT-Morphosys

 
17.05.03 11:35
Gestern von der Hauptversammlung vei Morphosys:
....
Kapitalerhöhungen
......
Im Dezember 2002 schloss MorphoSys einen Vergleich mit CAT, um den langjährigen Patentstreit
zu beenden. Als Teil der Vereinbarung wird MorphoSys 588.160 Aktien an CAT als Teilzahlung
für die Lizenz von CAT ausgeben. Die Aktienausgabe für CAT erfolgt voraussichtlich im zweiten
Halbjahr 2003.
Obwohl die beiden Kapitalerhöhungen eine Verwässerung des Altaktienbestandes bedeuten, so
konnten essentielle und sehr wertvolle Lizenzen von XOMA und CAT erworben werden. Durch
das Bezahlen mit Aktien konnten die liquiden Mittel des Unternehmens geschont werden was
vor allem dadurch an Bedeutung gewann, dass es uns nicht gelungen war, die in Aussicht genommenen
Partnerschaften einzugehen. Beim Vergleich aller Vor- und Nachteile überwiegen die
wirtschaftlichen Vorteile für MorphoSys und damit auch für unsere Aktionäre.
.......

Grüße
ecki  
first-henri:

Thanx, Morph halte ich übrigens für interessant

 
17.05.03 16:08
als Langfristinvestment.

Greetz f-h
Eskimato:

Cambridge, Ausbruch gen Norden mit News.

 
23.05.03 19:21
Cambridge Antibody Technology Reports Granting of Positive Opinion for HUMIRA(TM) By European Medicines Evaluation Agency  
       FRIDAY, MAY 23, 2003 12:48 PM
- PR Newswire

CAMBRIDGE, England, May 23, 2003 /PRNewswire-FirstCall via COMTEX/ -- Cambridge Antibody Technology (Nasdaq: CATG; LSE: CAT) today acknowledges the announcement by Abbott Laboratories that the European Medicines Evaluation Agency (EMEA) has granted a positive opinion on HUMIRA(TM) (adalimumab, previously known as D2E7) for the treatment of rheumatoid arthritis (RA). HUMIRA was isolated and optimised by CAT and Abbott Laboratories as part of a broad scientific collaboration. Abbott Laboratories filed for European Union (EU) approval in April 2002.

In an announcement dated 22 May 2003, Abbott Laboratories stated that the European Commission (EC) is expected to issue an authorization for marketing HUMIRA in EU countries in approximately 90 days. HUMIRA will be sent to pharmacies in Germany and the UK within two weeks of receipt of the marketing authorization.

CAT will receive royalties on the sales of HUMIRA. In addition, approval in a country other than the US will trigger a milestone payment to CAT from Abbott Laboratories.

Abbott Laboratories reported that the positive opinion on HUMIRA, granted through the EMEA's Committee for Proprietary Medicinal Products (CPMP), was based on data obtained in four controlled clinical trials. In total, 23 trials have been conducted with HUMIRA, involving more than 2,400 RA patients worldwide.

Abbott Laboratories also stated that HUMIRA will become the first human monoclonal antibody approved in Europe for RA, and the first tumour necrosis factor alpha antagonist approved with an indication for use with methotrexate or as monotherapy. HUMIRA is indicated for the treatment of moderate to severe active RA when the response to disease modifying anti-rheumatic drugs (DMARDs), including methotrexate, has been inadequate. To ensure maximum efficacy, HUMIRA is given in combination with methotrexate. HUMIRA can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.

As set out in CAT's interim results for the six months ended 31 March 2003, CAT's entitlement to royalties in relation to sales of HUMIRA is governed by an agreement dated 1 April 1995 between Cambridge Antibody Technology Limited and Knoll Aktiengesellschaft (now a subsidiary of Abbott Laboratories). The agreement allows for offset, in certain circumstances, of royalties due to third parties against royalties due to CAT, subject to a minimum royalty level. Abbott indicated to CAT in March 2003 its wish to initiate discussions regarding the applicability of these royalty offset provisions for HUMIRA. CAT believes strongly that the offset provisions do not apply and will seek an outcome consistent with that position.


    Notes to Editors
    Cambridge Antibody Technology (CAT):

     * CAT is a UK-based biotechnology company using its proprietary
       technologies and capabilities in human monoclonal antibodies for drug
       discovery and drug development. Based near Cambridge, England, CAT
       currently employs around 290 people.
     * CAT is a leader in the discovery and development of human therapeutic
       antibodies and has an advanced proprietary platform technology for
       rapidly isolating human monoclonal antibodies using phage display
       systems. CAT has extensive phage antibody libraries, currently
       incorporating more than 100 billion distinct antibodies. These
       libraries form the basis for the Company's strategy to develop a
       portfolio of antibody-based drugs.
     * HUMIRA(TM) is the leading CAT-derived antibody. Six other CAT-derived
       human therapeutic antibodies are at various stages of clinical trials.
     * CAT has alliances with a large number of pharmaceutical and
       biotechnology companies to discover, develop and commercialise human
       monoclonal antibody-based products. CAT has also licensed its
       proprietary human phage antibody libraries to several companies for
       target validation and drug discovery. CAT's collaborators include:
       Abbott, Amgen, Amrad, Chugai, Elan, Genzyme, Human Genome Sciences,
       Merck & Co, Pharmacia and Wyeth Research.
     * CAT is listed on the London Stock Exchange and on NASDAQ since June
       2001. CAT raised 41m pounds in its IPO in March 1997 and 93m pounds in
       a secondary offering in March 2000.


Application of the Safe Harbor of the Private Securities Litigation Reform Act of 1995: This press release contains statements about Cambridge Antibody Technology Group plc ("CAT") that are forward looking statements. All statements other than statements of historical facts included in this press release may be forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on numerous assumptions regarding CAT's present and future business strategies and the environment in which CAT will operate in the future. Certain factors that could cause CAT's actual results, performance or achievements to differ materially from those in the forward looking statements include: market conditions, CAT's ability to enter into and maintain collaborative arrangements, success of product candidates in clinical trials, regulatory developments and competition.

SOURCE Cambridge Antibody Technology

Peter Chambre, Chief Executive Officer, John Aston, Chief
Financial Officer or Rowena Gardner, Director of Corporate Communications,
+44-0-1223-471-471, all of Cambridge Antibody Technology; Graham Herring or
Kevin Smith, both of Weber Shandwick Square Mile (Europe), +44-0-20-7067-0700,
for Cambridge Antibody Technology; Brad Miles, ext. 17 (media), or Brandon
Lewis, ext. 15 (investors), both of BMC Communications-The Trout Group (USA),
+1-212-477-9007, for Cambridge Antibody Technology
(CATG)


Copyright (C) 2003 PR Newswire. All rights reserved.

Eskimato:

Abbott muss nachzahlen.

 
21.12.04 05:13
Gruss E.

LONDON (CBS.MW) - Shares of British biotech group Cambridge Antibody Technology surged 21 percent Monday after a U.K. court ruled in its favor against Abbott Laboratories over royalty payments.

Cambridge Antibody (CATG: news, chart, profile) said the High Court in London found Abbott (ABT: news, chart, profile) should have calculated higher royalty payments for the CAT-derived antibody arthritis treatment Humira. The court noted that in its short time on the market that Abbott's Humira sales "have been substantial."

Abbott on Monday sought permission to appeal, AFX News reported. Humira has been approved in 54 countries and prescribed to more than 83,000 patients suffering from rheumatoid arthritis worldwide. In the third quarter, Humira generated $145 million in U.S. sales, up 98 percent on the third quarter of 2003. Global sales totaled $227 million.

Judge Hugh Laddie said he came "to the conclusion that the construction advanced by CAT is correct and that the construction advanced by Abbott does violence to the language of the agreements, renders them obscure and makes little or no commercial sense."

The court found that "Abbott was in error when it made its first royalty payment to CAT calculated on the basis that only 2 percent of the net sales was due. It should have calculated on the basis of the full royalty of just over 5 percent."

CAT shares were last up 133 pence at 765.5 pence in London.
Auf neue Beiträge prüfen
Es gibt keine neuen Beiträge.


Hot-Stocks-Forum - Gesamtforum - Antwort einfügen - zum ersten Beitrag springen

Neueste Beiträge aus dem CAMBRIDGE AN.SP.ADR LS-,1 Forum

Wertung Antworten Thema Verfasser letzter Verfasser letzter Beitrag
  10 Gibt's Meinungen zu Cambridge Antibody ? first-henri Eskimato 21.12.04 05:13
  2 ambri jarif100 zacc 17.03.04 15:14
  4 ambri jarif100 taisir 17.03.04 12:12
  4 Super Gewinn steht bevor!!! superperformer Bullpark 23.02.04 16:14
  2 AMBRI vor der Explosion!!! superperformer Thomastradamus 23.02.04 15:27

--button_text--